Oncogenic Ras downregulates mdr1b expression through generation of reactive oxygen species

Semo Jun¹,†, Seok Won Kim²,†, Byeol Kim¹, In-Youb Chang³, and Seon-Joo Park¹,*

Departments of ¹Premedical Sciences, ²Neurosurgery, and ³Anatomy, College of Medicine, Chosun University, Gwangju 61452, Korea

ABSTRACT In the present study, we investigated the effect of oncogenic H-Ras on rat mdr1b expression in NIH3T3 cells. The constitutive expression of H-RasV12 was found to downregulate the mdr1b promoter activity and mdr1b mRNA expression. The doxorubicin-induced mdr1b promoter activity of the H-RasV12 expressing NIH3T3 cells was markedly lower than that of control NIH3T3 cells. Additionally, there is a positive correlation between the level of H-RasV12 expression and a sensitivity to doxorubicin toxicity. To examine the detailed mechanism of H-RasV12-mediated down-regulation of mdr1b expression, antioxidant N-acetylcysteine (NAC) and NADPH oxidase inhibitor diphenylene iodonium (DPI) were used. Pretreating cells with either NAC or DPI significantly enhanced the oncogenic H-Ras-mediated down-regulation of mdr1b expression and markedly prevented doxorubicin-induced cell death. Moreover, NAC and DPI treatment led to a decrease in ERK activity, and the ERK inhibitors PD98059 or U0126 enhanced the mdr1b-Luc activity of H-RasV12-NIH3T3 and reduced doxorubicin-induced apoptosis. These data suggest that RasV12 expression could downregulate mdr1b expression through intracellular reactive oxygen species (ROS) production, and ERK activation induced by ROS, is at least in part, contributed to the downregulation of mdr1b expression.

INTRODUCTION

The development of acquired resistance to anticancer drugs is a major obstacle to the curative use of these drugs. Multiple mechanisms have been suggested in the development of multidrug resistance (mdr), and the P-glycoprotein (Pgp) encoded by the multidrug resistance type 1 (MDR1) genes has been identified as a major mechanism in the development of anticancer drug resistance [1,2]. MDR1 contributes to multidrug resistance in humans, and mdr1a and mdr1b cause multidrug resistance to rodents. P-glycoprotein overexpression is generally believed to reduce cellular drug accumulation because of the enhanced drug efflux of various structurally and functionally unrelated anticancer drugs, these include anthracycline (e.g., doxorubicin), vinca alkaloids and antibiotics [3]. Therefore, enhanced human MDR1 gene expression is believed to be contributed to the treatment failure of some human cancers. Furthermore, it has been postulated that the mdr1 gene is a marker of tumor progression and aggressiveness.

Ras plays an important role in cellular proliferation and differentiation [4], and point mutations in the Ras gene occur frequently in mammalian cells, leading to the transformation and advanced tumor progression [5]. The relationship between oncogenic Ras expression and drug resistance in some human tumors has been investigated. Although several studies concerning MDR expression have been performed in oncogenic Ras transformed cells, the role of Ras in MDR expression is still unknown. Several studies have reported that active Ras causes MDR1 expression and leads to anticancer drug resistance [6-8]. However, others have found that Ras activation was not able to up-regulate the
MDR1 gene [9], and that oncogenic Ras overexpression resulted in the downregulation of MDR1 expression and a subsequent reduction in surface-localized Pgp [10,11].

Reactive oxygen species (ROS) is a downstream effector of Ras, and can influence a number of intracellular pathways. ROS also act as a second messenger in the cells and control various Ras-associated intracellular effects [12-14]. Recently, it has been suggested that Pgp expression may be regulated by a redox-sensitive signal pathway, because the rat mdr1b gene promoter contains redox-sensitive transcriptional factors, including activated protein-1 (AP-1) or nuclear factor κB (NF-κB) [15,16]. Moreover, intracellular ROS production can modulate rat mdr1b gene expression [17,18]. Therefore, the question as to whether or not the oncogenic Ras effects mdr1b expression, and whether or not ROS, as a downstream effector of Ras, is involved in mdr1b expression, was addressed. Here, we report that the stable expression of oncogenic H-Ras significantly decreases mdr1b expression in NIH3T3 cells, and that treating V12-Ras expressing cells with either antioxidant N-acetylcysteine (NAC) or the NADPH oxidase inhibitor diphenylene iodonium (DPI) lead to an increase in mdr1b expression and the prevention of doxorubicin-induced apoptosis. Using the ERK inhibitors, PD98059 and U0126, evidence is provided showing that ERK activity is, at least in part, involved in the ROS-mediated down-regulation of mdr1b expression in V12-Ras-NIH3T3 cells.

METHODS

Cell culture and reagents

The NIH3T3 mouse embryo fibroblast lines were obtained from American Type Culture Collection (ATCC; Manassas, VA, USA) and were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 units/ml of penicillin, and 100 μg/ml of streptomycin (Life Technologies, Inc., Carlsbad, CA, USA). Cells were cultured at 37°C in a humidified chamber containing 5% CO2. Doxorubicin, NAC, DPI and propidium iodide were purchased from Sigma (St. Louis, MO, USA), anti-Ras polyclonal antibody from BD Transduction Laboratories (Ann Arbor, MI, USA). Membranes were subsequently incubated with anti-Ras polyclonal antibody (BD Transduction Laboratories) at 4°C overnight, followed by peroxidase-conjugated secondary antibodies for 1 h at room temperature. The bands were visualized by an ECL chemiluminescent detection system (iNiTRON Biotechnology, Seongnam, Korea).

Plasmid constructs and oligonucleotides

Wild type H-Ras cDNA was cloned by RT-PCR from human Jurkat cells. The dominant positive H-Ras (RasV12) and dominant negative H-Ras (RasN17) were subjected to site-directed mutation using the wild type H-Ras cDNA template, according to the manufacturer's instruction (Stratagene, La Jolla, CA, USA). After DNA sequence confirmation, the V12-Ras and N17-Ras cDNA were subcloned into a pcDNA3 mammalian expression vector (Invitrogen, San Diego, CA, USA), respectively. pGL3-Luc plasmid was purchased from Promega (San Diego, CA, USA), Gal4-ELK1 and pFR-Luc plasmids were purchased from Stratagene (La Jolla, CA, USA), and mdr1b-Luc plasmid was generously provided by M. Tien Kuo [19]. The c-jun N-terminal kinase (JNK) antisense (AS) oligonucleotides used in this study were synthesized at ISIS Pharmaceuticals, Inc. (Carlsbad, CA, USA). The sequences of the oligonucleotides used were as follows: Control (ISIS 17552), TCAGTAATTAGCCCCACATGG; JNK1 AS (ISIS 15347), CTCTGTAGGCCCGCTTGG; and JNK2 AS (ISIS 15354), GTCCGGGCCAG-GCCAAAGTC. All oligonucleotides were 2’-O-methoxymethyl chimeras containing five 2’-O-methoxyethyl-phosphodiester residues flanking a 2’-deoxynucleotide-phosphorothioate region [20].

Transfection and luciferase activity assay

NIH3T3 cells were transfected with reporter vectors (mdr1b-Luc, pGL3-Luc, Gal4-ELK1 or pFR-Luc) and pRL-CMV (renilla luciferase containing vector) using LipofectAMINE and LipofectAMINE PLUS solution, according to the manufacturer's instruction (Life Technologies, Inc.). Dual luciferase activity in the cell extracts was determined according to manufacturer’s instructions (Promega). Briefly, each assay mixture contained 20 l cell lysate and firefly luciferase measuring buffer (LAR II®; Promega). Firefly luciferase activity was then measured using a luminometer. The reaction mixture was then added to renilla luciferase measuring buffer (Stop & Glo®; Promega). Renilla luciferase activity was used to normalize transfection efficiency. The level of luciferase activation is presented relative to the activity obtained from the transfection of mdr1b-Luc into the pcDNA3-NIH3T3 cells, whose value was placed at 1.0.

Western blotting

Cell extracts were prepared in RIPA buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM DTT) containing protease inhibitors (Roche, Basel, Switzerland). Proteins were separated by SDS-PAGE and transferred onto a PVDF membrane (PALL life Sciences, Ann Arbor, MI, USA). Membranes were subsequently incubated with anti-Ras polyclonal antibody (BD Transduction Laboratories) at 4°C overnight, followed by peroxidase-conjugated secondary antibodies for 1 h at room temperature. The bands were visualized by an ECL chemiluminescent detection system (iNiTRON Biotechnology, Seongnam, Korea).

Apoptosis assay

Cells were collected 24 h after being treated, fixed in 70% ethanol, and stained with propidium iodide (PI, 50 μg/ml) after RNA
H-Ras downregulates mdr1b expression

digestion. 10,000 PI-stained cells were analyzed for DNA content using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA).

RT-PCR

The total RNA was isolated from pcDNA3-NIH3T3 and V12-Ras-NIH3T3 cells using TRIzol Reagent according to the manufacturer’s instruction. The total RNA (1 μg) of the total RNA was reverse transcribed using MMLV reverse transcriptase (Gibco BRL) in its own buffer and random primers at 37°C for 1 h. cDNA amplification was done by PCR through 35 cycles at 94°C for 30 sec, 55°C for 30 sec, and 72°C for 45 sec, followed by a final step at 72°C for 5 min. The following rat primers designed were used as previously reported [21]: mdr1b sense primer, 5’-GAAATAATGCTTATGAATCCAA-3’; mdr1b antisense primer, 5’-GGTTTTCAGTGGTGTCTTGTA-3’; GAPDH sense primer, TGTGAACGGATTTGGCCTA-3’; GAPDH antisense primer, 5’-TCGC TCCTGGAAGATGGTGA-3’. After amplification, the PCR products were separated by 1.5% agarose gel electrophoresis and stained with ethidium bromide and the resulting bands were analyzed by densitometry.

Statistical analysis

All experiments were done with at least three times independently. Data were represented as mean ± standard deviation. Statistical comparisons were determined by Two-tailed Student’s t-test using GraphPad prism software (GraphPad software, Inc., La Jolla, CA, USA) and Excel (Microsoft, Redmond, WA, USA). p-values < 0.05 was considered statistically significant.

Fig. 1. Effect of oncogenic H-Ras overexpression on mdr1b expression. (A) The levels of overexpressed V12-Ras was analyzed by Western blotting. (B) The pcDNA3-NIH3T3 (vector) and V12-Ras-NIH3T3 (V12-Ras) cells were cotransfected with either mdr1b-Luc or pFR-Luc and pRL-Luc. The luciferase activities were measured 24 h after transfection, as described under “Methods”. Transfection with the pRL-Luc plasmid was used to normalize the transfection. The level of luciferase activation is presented relative to the activity obtained from the transfection of mdr1b-Luc into the pcDNA3-NIH3T3 cells, whose value was placed at 1.0. To block the Ras signaling pathway, N17-Ras-pcDNA3 (N17-Ras) was transiently transfection into V12-Ras-NIH3T3 cells, after which cells were transfected with mdr1b-Luc. Each data bar represents the mean of five observations from three independent experiments; the error bars indicate ± standard deviation. (C) RT-PCR analysis of mdr1b gene expression in pcDNA3-NIH3T3 (vector), V12-Ras-NIH3T3 (V12) and N17-Ras transfecing V12-Ras-NIH3T3 cells (V12+N17). The total RNA (2 μg) was reverse transcribed using reverse transcriptase. cDNA amplification was carried out using taa-polymerase over 30 cycles. The PCR products were separated on 1.5% agarose gels, stained with ethidium bromide. Bar graphs quantify the amount of mdr1b mRNA by Image J software. **p < 0.01.
RESULTS

Expression of oncogenic H-Ras inhibits rat mdr1b expression

In order to determine the role of oncogenic Ras in the mdr1b gene expression, the dominant positive form of Ras\(^{\text{V12}}\) and an empty expression (pcDNA3) vector were stably transfected into NIH3T3 cells. Following selection by G418, several clones were isolated and one Ras\(^{\text{V12}}\)-NIH3T3, which expressed oncogenic H-Ras, and one pcDNA3-NIH3T3, which was used as a control, were selected for further test. Immunoblotting analysis revealed that Ras\(^{\text{V12}}\)-NIH3T3 cells exerted significant overexpression of oncogenic H-Ras as opposed to that of the pcDNA3-NIH3T3 cells (Fig. 1A). To investigate whether or not Ras\(^{\text{V12}}\) might modulate mdr1b expression in NIH3T3 cells, the luciferase activities were determined by a luminometer in the Ras\(^{\text{V12}}\) and pcDNA3 expressing cells, which were cotransfected with the mdr1b-Luc reporter plasmid or the pFR-Luc plasmid and the pRL-Luc plasmid containing the renilla luciferase gene. As shown in Fig. 1B, we found that Ras\(^{\text{V12}}\) markedly inhibited the mdr1b-Luc activities in the NIH3T3 cells. Luciferase activity analysis revealed that the Ras\(^{\text{V12}}\) NIH3T3 cells had 75\% less mdr1b-Luc activity than the pcDNA3-NIH3T3 cells. However, Ras\(^{\text{V12}}\) expression had no effect on pFR-Luc. This result suggests that Ras\(^{\text{V12}}\) can downregulate mdr1b expression in NIH3T3 cells. To confirm the inhibitory effect of Ras\(^{\text{V12}}\) on the mdr1b-luc activity, dominant negative Ras containing plasmid (Ras\(^{\text{N17}}\)) was transfected into Ras\(^{\text{V12}}\)-NIH3T3 cells and the luciferase activities were measured. As shown in Fig. 1C, the decrease in the mdr1b-Luc activity by Ras\(^{\text{V12}}\) can be increased by Ras\(^{\text{N17}}\) expression, indicating that the decrease in mdr1b-Luc activity results from Ras\(^{\text{V12}}\) expression. To further investigate the role of Ras\(^{\text{V12}}\) in the downregulation of mdr1b expression in NIH3T3 cells, mdr1b mRNA expression in the pcDNA3-NIH3T3 and Ras\(^{\text{V12}}\)-NIH3T3 cells was determined by RT-PCR analysis. As shown in Fig. 1B, the mdr1b mRNA expression level appeared to be quite low in the Ras\(^{\text{V12}}\)-NIH3T3 cells compared to that observed in the pcDNA3-NIH3T3 cells. Densitometric analysis exhibited that the level of mdr1b mRNA in pcDNA3-NIH3T3 cells was approximately 3-fold higher than that in Ras\(^{\text{V12}}\)-NIH3T3 cells.

We next investigated whether Ras\(^{\text{V12}}\) expression would affect the doxorubicin-induced mdr1b-Luc activity. For this experiment, pcDNA3-NIH3T3 and Ras\(^{\text{V12}}\)-NIH3T3 cells were transfected with the mdr1b-Luc reporter plasmid, subsequently treated with doxorubicin, and luciferase activity was then determined. We found that, in the pcDNA3-NIH3T3 cells, treatment with 50, 100, and 250 nM of doxorubicin increased the mdr1b-Luc activity by 150-, 200-, and 300-fold compared to the untreated cells, respectively. However, in the V12-Ras-NIH3T3 cells, the corresponding enhancements of mdr1b-Luc activities were only 110-, 120-, and 150-fold versus the untreated cells (Fig. 2). These data indicate that Ras\(^{\text{V12}}\) expression lead to down-regulation of the basal and doxorubicin-induced mdr-1b expression in NIH3T3 cells.

Intracellular ROS production by the expression of oncogenic Ras inhibits mdr1b expression

H-Ras expression has been reported to increased intracellular ROS generation in several cell lines [22-25]. For this reason, the level of intracellular ROS production was investigated using DCFHDA. Fig. 3 shows that Ras\(^{\text{V12}}\) expression significantly increased the intracellular ROS production, which was blocked...
by RasV12 expression. In addition, treatment with either a thiol reducing agent NAC or NADPH oxidase inhibitor DPI dramatically reduced the level of intracellular ROS generation induced by RasV12 transfection. These results suggest that activating NADPH oxidase activity by RasV12 expression is involved in the intracellular ROS generation.

To investigate the possibility that the enhancement in intracellular ROS levels by RasV12 expression contributes to the downregulation of mdr1b expression, we tested whether or not antioxidant increased mdr1b expression in RasV12-NIH3T3 cells. For this purpose, RasV12-NIH3T3 cells were treated with either DPI or NAC, and then cotransfected with mdr1b-Luc reporter plasmid or the pFR-Luc plasmid. After 24 h transfection, the mdr1b promoter activity and its mRNA level were then measured by a luminometer and RT-PCR, respectively. The data presented in Fig. 4A shows that both NAC and DPI were able to increase mdr1b-Luc activity in RasV12-NIH3T3 cells compared to the non-treated cells. However, both DPI and NAC did not affect pFR-Luc. Furthermore, RT-PCR data revealed that pretreating the RasV12-NIH3T3 cells with either NAC or DPI up-regulated mdr1b mRNA expression (Fig. 4B). Intracellular ROS was next investigated to determine whether or not it affected the doxorubicin-induced mdr1b promoter activity. As shown in Fig. 5, we found that mdr1b-Luc activity in the RasV12-NIH3T3 cells was significantly enhanced after increasing the doxorubicin dose in the presence of DPI and NAC versus the untreated control. These data indicate that intracellular ROS production is required for the RasV12-induced downregulation of mdr1b expression in NIH3T3 cells.

**Involvement of ERK signal transduction in the downregulation of mdr1b expression**

ROS proposed to stimulate mitogen-activated protein kinase (MAPK) activities including ERK, p38 and JNK [26]. Thus, increased ROS generation by RasV12 expression was investigate to determine whether it caused ERK activation, which would contribute to downregulation of mdr1b expression. To test this possibility, the pcDNA3-NIH3T3 or RasV12-NIH3T3 cells were treated with either DPI or NAC, and were subsequently co-transfected with Gal4-Elk1 or pFR-Luc. Twenty-four hours after transfection, the level of luciferase activity was measured. Elk1 is a transcription factor that is activated by MAPK signaling. The Gal4-Elk1 construct contains the Gal4 DNA binding domain fused to the Elk-1 carboxyl-terminal transactivation domain. The results, shown in Fig. 6A, demonstrated that RasV12-NIH3T3 cells exhibited a significantly increase in ERK activity versus the pcDNA3-NIH3T3 cells, and the suppression of ROS production by treatment with either DPI or NAC resulted in the inhibition of Ras activation of Gal4-Elk1 by 50%, but NAC and DPI had no effect on pFR-Luc. As a control, ERK inhibitors PD98059 and U0126 were found to completely block the H-RasV12-activation of ERK activity. ERK activity was next investigated to determine whether or not it contributes to the Ras-mediated downregulation of mdr1b expression. The RasV12-NIH3T3 cells were treated with DMSO, PD98059, or U0126. The cells were then cotransfected with Gal4-Elk1 or pFR-Luc, 48 h transfection, cells were treated with or without 250 nM doxorubicin. After 24 h, the levels of luciferase activity were then measured. Pretreatment of RasV12-NIH3T3 cells with either PD98059 or U0126 increases the basal level of mdr1b-Luc activity compared with that of the untreated

---

**Fig. 4. Effect of N-acetylcysteine (NAC) and diphenylene iodonium (DPI) on basal level of mdr1b expression.** (A) The V12-Ras-NIH3T3 (V12-Ras) cells were pretreated with either 20 mM NAC or 500 nM DPI for 12 h, and then cotransfected with either mdr1b-Luc or pFR-Luc and pRL-Luc. The luciferase activities were the luciferase activity was determined as described in Fig. 1A. Each point is the average of multiple independent experiments; the error bars represent ± standard deviation. (B) RT-PCR analysis of the mdr1b gene expression level in V12-Ras-NIH3T3 cells with NAC or DPI. The cells were pretreated with either NAC or DPI for 12 h. RT-PCR was performed with the total RNA extract (20 μg) and the PCR products were separated on 1.5% agarose gels, and stained with ethidium bromide. *p < 0.05, **p < 0.01 vs. untreated.
cells. Furthermore, blocking the ERK signaling pathway led to the stimulation of the doxorubicin-induced mdr1b-Luc activity versus the untreated cells (Fig. 6B).

To address the potential contribution of JNK and p38 in the RasV12-mediated downregulation of mdr1b expression, RasV12-NIH3T3 cells were treated with the P38 kinase inhibitor, SB203580 or transfected with antisense JNK1 and JNK2, which inhibit JNK pathway [20]. They were then transfected with the mdr1b-Luc reporter plasmid. After 24 h, the luciferase activities were measured. As shown in Fig. 6C, the blocking of these signaling pathways had little effect on mdr1b expression in the RasV12-NIH3T3 cells. These results suggest that ERK activity, but not JNK and p38, contributes to the ROS-mediating down-regulation of mdr1b expression in the V12-Ras-NIH3T3 cells.

Fig. 5. Effect of N-acetylcysteine (NAC) and diphenylene iodonium (DPI) on the induction level of mdr1b expression by doxorubicin (DOX). The V12-Ras-NIH3T3 cells were pretreated with 20 mM NAC or 500 nM DPI for 12 h and then cotransfected with either mdr1b-Luc or pFR-Luc and pRL-Luc. Four hours after transfection, the cells were treated with 50, 100, or 250 nM doxorubicin for 24 h, after which the luciferase activities were determined as described in Fig. 1A. Each point is the average of multiple independent experiments; the error bars represent ± standard deviation. *p < 0.05 vs. untreated. **p < 0.01.

Fig. 6. Effect of ERK signaling pathway in the regulation of mdr1b expression. (A) pcDNA3-NIH3T3 (vector) and V12-Ras-NIH3T3 (V12-Ras) cells were pretreated with either DMSO or the indicated compounds, at the following concentrations: 50 μM PD98059, 20 μM U0126, 10 mM NAC, and 500 nM DPI. Subsequently, the cells were cotransfected with either the Gal4-Elk1 or pFR-Luc plasmid and pRL-CMV. The luciferase activities were then measured 24 h after transfection determined as described in Fig. 1A. (B) V12-Ras-NIH3T3 cells were incubated 50 μM PD98059 or 20 μM U0126 for 30 min and then cotransfected with mdr1b-Luc and pRL-Luc. Four hours after transfection the medium was replaced with fresh medium in the presence or absence of 250 nM doxorubicin (DOX), and 24 h later, the luciferase activities were determined as described in Fig. 1A. (C) V12-Ras-NIH3T3 cells were pretreated with DMSO or p38 inhibitor 20 μM SB2303580, or transiently transfection with a combination of JNK1AS and JNK2AS (JNK1+2AS) or control oligonucleotides (control JNK). The cells were then cotransfected with mdr1b-Luc and pRL-Luc, and the luciferase activities were determined as described in Fig. 1A. Each point is the average of multiple independent experiments; the error bars represent ± standard deviation. *p < 0.05 vs. V12-Ras, **p < 0.01 vs. vector, and ***p < 0.001 vs. V12-Ras.
**DISCUSSION**

A high frequency of point mutations in the Ras gene, which occurs in approximately 30% of human cancers, can lead to a transformation and advanced tumor progression [4,5]. Oncogenic mutation of Ras has been reported to be involved in tumorigenesis in various human tumors, so discovering the molecular mechanisms of Ras-mediated mdr1b regulation can result in superior cancer management. In spite of several reports on the effect of oncogenic Ras on the MDR expression, there are inconsistent results regarding the relation between oncogenic Ras and mdr expression. The transformation of rat liver epithelial cells with the Ras oncogene caused appearance of MDR [6]. In addition, the promoter of the mdr1 gene was shown to be a potential target for the H-Ras oncogene [27], which suggests that the mdr1 gene could be activated during the tumor progression related with oncogenic H-Ras. Therefore, it is possible that oncogenic Ras could up-regulate mdr1b gene expression. However, others have suggested that an oncogenic Ras transformation had no effect on mdr-1 gene expression [9] and H-Ras expression led to the downregulation of mdr-1 gene expression in human colon carcinoma and acute myeloid leukemia cells [10,11]. In this study, we tries to determine the relationship between dominant active H-Ras and mdr1b expression. In order to understand the possible role of oncogenic H-Ras in mdr1b expression, NIH3T3 cells were transfected either with the dominant active H-Ras expression plasmid, Ras[V12]-pcDNA3 or an empty expression plasmid, pcDNA3. To determine the mdr1b expression level, a reporter assay was used for measuring the mdr1b promoter activity and a RT-PCR assay was used for measuring the expression of mdr1b mRNA level. Oncogenic Ras expression was found to lead to the down-regulation of mdr1b expression and dominant negative Ras (Ras[N17]) prevented the Ras[V12]-mediated decrease in mdr1b promoter activity. In addition, the Ras[V12]-NIH3T3 cells exhibited a decrease in doxorubicin-induced mdr1b-Luc activity (Figs. 1 and 2) and potentiate doxorubicin-induced apoptosis compared to the control cells. These results indicate that oncogenic H-Ras expression is contributed to the downregulation of mdr1b expression.

Although ROS are thought to be toxic to cells, it has recently been reported that ROS act as secondary messenger that regulates the cellular proliferation in variety of eukaryotic cells [26,28]. The oncogenic Ras produced ROS in NIH3T3 [22], HaCat [23], and WI38 cells [25]. It is believed that these ROS generation is induced by Ras-mediated NADPH oxidase activity, which is located in the cellular membrane in non-phagocytic cells. It was confirmed that Ras[V12] expression increased ROS generation, which was reduced by Ras[S33] or by DPI. The promoter of rat mdr1b gene contains several transcriptional factor-binding sites, such as AP-1, NF-κB, NF-Y and p53 [29-32], and it is these factors that exhibit redox-sensitivity [33-35]. Several reports have shown that mdr1b can be induced by intracellular ROS production [17,18] and that the activation of the NF-κB redox-sensitive transcriptional fac-

---

**The effect of mdr1b expression on cellular response to doxorubicin**

If the intracellular ROS production and ERK activation play an importing role in the Ras-mediated downregulation of mdr1b expression, then the agents capable of inhibiting ROS production and blocking ERK activity, when combined with doxorubicin treatment, should inhibit their cytotoxicity. To test this possibility, doxorubicin-induced apoptosis in Ras[V12]-NIH3T3 and pcDNA3-NIH3T3 cells with or without antioxidant and MEK inhibitors were compared. As shown in Fig. 7, doxorubicin increased apoptosis with increasing doses, and a dose of 250 nM doxorubicin led to induced approximately 40% apoptosis after 24 h of treatment in control NIH3T3 cells. In contrast, the Ras[V12]-NIH3T3 cells showed very high sensitivity to doxorubicin and apoptosis was great than 90% at the concentration of 250 nM doxorubicin. However, the combination of either doxorubicin with NAC or DPI reduced the apoptotic response of the Ras[V12]-NIH3T3 cells, and treatment of the Ras[V12]-NIH3T3 cells with the ERK inhibitors reduced apoptotic response versus the untreated cells.
tors by intracellular ROS production may be involved in mdr1b induction [19]. However, other studies have reported that an enhancement of ROS levels downregulates Pgp expression [36] and that this downregulation is mediated by activating the receptor tyrosine kinase pathway [37]. In the present study, evidence that intracellular ROS is important for the down-regulation of mdr1b expression in V12-Ras-NIH3T3 cells was provided. Pre-treatment of V12-Ras-NIH3T3 cells with NAC and DPI led to an effective increase in mdr1b promoter activity and mdr1b mRNA expression (Figs. 4 and 5). This suggests that Ras overexpression could down-regulate mdr1b expression via the enhancement of intracellular ROS. A number of stresses and chemicals, such as, UV irradiation [38], heat stress [39], TNF-α [40] and benzopyrine [41] are able to induce Pgp expression. Most of these stress factors are known to stimulate production of large amount of ROS. However, induction of mdr1b expression in response to H2O2 treatment at concentrations in excess of 1 mM [18] may be associated with various physiological responses in cells. This is because these concentrations are highly toxic to cells, and would cause apoptosis [18,37]. Therefore, Pgp may have an important role in preventing apoptosis under severe oxidative stress, presumably by regulating the anti-apoptotic or apoptotic protein [42,43]. Low H2O2 concentrations (< 10 μM) are effective in activating ERK [44] and regulating cell proliferation [45]. Moreover, these concentrations are markedly lower than those necessary to trigger apoptosis [46]. Therefore, ROS levels can have different concentration-dependent roles in the regulation of MDR expression.

Important questions remaining are: how do ROS cause the mdr1b downregulation? What are the downstream factors contributed to mdr1b expression? Indeed, intracellular ROS can modulate many signal transduction pathways. However, the downstream effectors of ROS remains unclear. There is increasing number of reports that intracellular ROS level is physiologically related to regulating gene expression and activating MAPK. A recent study suggests that JNK activation plays an important intracellular regulator in response to various anticancer drugs and can affect the MDR phenotype [47,48]. In addition, MDR phenotype of the L120/VCR mouse leukemic cells was associated with increased p38 [49]. Moreover, increased ERK activity was attribute to MDR-1 overexpression in Taxol-resistance cell lines [50]. However, Osborn et al. [51] reported that the induction of MDR1 is required for the PKC activity, but ERK, p38 or JNK had no effect on MDR1 expression in K562 cells. However, in this study it was the inhibition of the ERK pathway, but not p38 and JNK, led to enhanced mdr1b promoter activity and inhibited doxorubicin-mediated apoptosis induction in RasV12-expressing cells (Fig. 6). The activation of the ERK pathway is known to have a role in the pro-survival signal against various toxic stimuli [52]. However, recent several studies have been reported that the suppression of ERK pathway cause enhanced sensitivity to anticancer drugs [53]. Moreover, ERK activation is also contributed to in the development of apoptosis in B lymphoma cells [54], neuronal cells [55], HeLa and human lung A549 cells [56]. In this system using NIH3T3 cells, a strong correlation between inhibiting the ERK pathway and a resistance to doxorubicin toxicity was found (Fig. 7B), indicating that ERK contributes to the downregulation of mdr1b expression. The Raf/ERK/MEK cascade is a major downstream signaling pathway of oncogenic Ras [57]. Therefore, there is the possibility that ERK activation induced by V12-Ras expression acts directly to down-regulate mdr1b expression. However, the direct contribution of ERK to mdr1b inhibition by oncogenic Ras does not appear to be significant, because blocking ROS generation significantly decreased mdr1b expression and prevented doxorubicin-induced apoptosis. Furthermore, treating the V12-Ras-NIH3T3 cells with either NAC or DPI led to a decrease ERK activity. Some cancer cells promote cell growth by increasing intracellular ROS generation [45]. The intracellular ROS concentration of these cancer cells may contribute to the downregulation of mdr-1 level. Consequently, measuring the ROS concentration and ERK activity would be useful strategy for predicting which cancers may respond to anticancer drugs. Although the molecular mechanism by which mdr1 mRNA expression is reduced by increasing ERK activity is currently unclear, however, since ERK activity modulates gene expression by increasing or inhibiting the activity of various transcription factors, we speculate that the increase in ERK induced by ROS suppresses the activity of certain transcription factors acting on the mdr1 promoter, resulting in a decrease in mdr1 expression. It will be clarified through future research.

In conclusion, the current findings provide strong evidence that oncogenic Ras overexpression in NIH3T3 cells leads to the down-regulation of mdr1b expression through intracellular ROS production, and that the ERK activation induced by ROS, at least in part, participates in down-regulating mdr1b expression.

ACKNOWLEDGEMENTS
This work is supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT, and Education (NRF-2015R1A5A2009070, NRF-2018R1D1A1B07048069).

CONFLICTS OF INTEREST
The authors declare no conflicts of interest.

REFERENCES
1. Nakai E, Park K, Yawata T, Chihara T, Kumazawa A, Nakabayashi H, Shimizu K. Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Invest. 2009;27:901-908.
H-Ras downregulates mdr1b expression

2. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48-58.
3. Silva R, Vilas-Boas V, Carmo H, Dinis-Oliveira RJ, Carvalho F, de Lourdes Bastos M, Remião F. Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. Pharmacol Ther. 2015;149:1-123.
4. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:349-465.
5. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72:2457-2467.
6. Burt RK, Garfield S, Johnson K, Thorgerisson SS. Transformation of rat liver epithelial cells with v-H-ras or v-raf causes expression of MDR-1, glutathione-S-transferase-P and increased resistance to cytotoxic chemicals. Carcinogenesis. 1986;9:2329-2332.
7. Wishart GC, Plumb JA, Spandidos DA, Kerr DJ. H-ras infection in mink lung epithelial cells may induce “atypical” multidrug resistance. Eur J Cancer. 1991;27:673.
8. Sabattini AR, Basolo F, Valentini P, Mattii L, Calvo S, Fiore L, Ciardiello F, Petrini M. Induction of multidrug resistance (MDR) by transfection of MCF-10A cell line with c-Ha-ras and c-erbb-2 oncogenes. Int J Cancer. 1994;59:208-211.
9. Di Simone D, Galimberti S, Basolo F, Ciardiello F, Petrini M, Scheper RJ. c-Ha-ras transfection and expression of MDR-related genes in MCF-10A human breast cancer cell line. Anticancer Res. 1997;17(5A):3587-3592.
10. Schaich M, Ritter M, Illmer T, Lisske P, Thiede C, Schakel U, Mohr B, Ehninger G, Neubauer A. Mutations in ras proto-oncogenes are associated with lower mdrl gene expression in adult acute myeloid leukaemia. Br J Haematol. 2001;112:300-307.
11. Kramer R, Weber TK, Arceci R, Morse B, Simpson H, Steele GD Jr, Summerhayes IC. Modulation of mdrl expression by a H-ras oncogene in a human colon carcinoma cell line. Int J Cancer. 1993;54:275-281.
12. Ferro E, Goitre L, Retta SF, Trabalzini L. The interplay between ROS and Ras GTPases: physiological and pathological implications. J Signal Transduct. 2012;2012:365769.
13. Archer H, Bar-Sagi D. Ras and Rac as activators of reactive oxygen species (ROS). Methods Mol Biol. 2002;189:67-73.
14. Xu W, Trepel J, Neckers L, Ras, ROS and proteotoxic stress: a delicate balance. Cancer Cell. 2011;20:281-282.
15. Yu C, Argyropoulos G, Zhang Y, Kastin AJ, Hsouchou H, Pan W. Neuroinflammation activates Mdr1b efflux transport through NF-kappaB: promoter analysis in BBB endothelia. Cell Physiol Biochem. 2008;22:745-756.
16. Silverman JA, Hill BA. Characterization of the basal and carcinogenic regulatory elements of the rat mdrl promoter. Mol Carcinog. 1995;13:50-59.
17. Hirsch-Ernst KI, Kietzmann T, Ziemann C, Jungermann K, Kahl GF. Physiological oxygen tensions modulate expression of the mdrl multidrug-resistance gene in primary rat hepatocyte cultures. Biochem J. 2000;350 Pt 2:434-451.
18. Ziemann C, Burké A, Kahl GF, Hirsch-Ernst KI. Reactive oxygen species participate in mdrlb mRNA and P-glycoprotein overexpression in primary rat hepatocyte cultures. Carcinogenesis. 1999;20:407-414.
19. Deng L, Lin-Lee YC, Claret FX, Kuo MT. 2-acetylaminofluorene up-regulates rat mdrlb expression through generating reactive oxygen species that activate NF-kappa B pathway. J Biol Chem. 2001;276:413-420.
20. Bost F, McKay R, Dean N, Mercola D. The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells. J Biol Chem. 1997;272:33422-33429.
21. Lehmann T, Köhler C, Weidauer E, Taege C, Foth H. Expression of MRP1 and related transporters in human lung cells in culture. Toxicology. 2001;167:59-72.
22. Irani K, Xia Y, Adeyewa JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science. 1997;275:1649-1652.
23. Yang JQ, Li S, Domann FE, Buettner GR, Oberley LW. Superoxide generation in v-Ha-ras-transduced human keratinocyte HaCaT cells. Mol Carcinog. 1999;26:180-188.
24. Huang WJ, Tung CW, Ho C, Yang JT, Chen ML, Chang PJ, Lin CL, Wang JY. Ras activation modulates methylglyoxal-induced mesangial cell apoptosis through superoxide production. Ren Fail. 2007;29:911-921.
25. Liu R, Li B, Qiu M. Elevated superoxide production by active H-ras enhances human lung WI-38VA-13 cell proliferation, migration and resistance to TNF-alpha. Oncogene. 2001;20:1486-1496.
26. Gupta A, Rosenberger SF, Bowden GT. Increased ROS levels contribute to elevated transcription factor and MAP kinase activities in malignantly progressed mouse keratinocyte cell lines. Carcinogenesis. 1999;20:2063-2073.
27. Chin KV, Ueda K, Paslan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 1992;255:459-462.
28. Son Y, Cheong YK, Kim NH, Chung HT, Kang DG, Pae HO. Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways? J Signal Transduct. 2011;2011:792639.
29. Zhou G, Kuo MT. Wild-type p53-mediated induction of mdrlb expression by the anticancer drug daunorubicin. J Biol Chem. 1998;273:15387-15394.
30. Zhou G, Kuo MT. NF-kappaB-mediated induction of mdrlb expression by insulin in rat hepatoma cells. J Biol Chem. 1997;272:15174-15183.
31. Yu L, Cohen D, Piekarcz RL, Horwitz SB. Three distinct nuclear protein binding sites in the promoter of the murine multidrug resistance mdrlb gene. J Biol Chem. 1993;268:7520-7526.
32. Yu L, Wu Q, Yang CP, Horwitz SB. Coordination of transcription factors, NF-Y and C/EBP beta, in the regulation of the mdrlb promoter. Cell Growth Differ. 1995;6:1505-1512.
33. Yin Z, Machius M, Nestler EJ, Rudenko G. Activator protein-1: redox switch controlling structure and DNA-binding. Nucleic Acids Res. 2017;45:11425-11436.
34. Novitskii VV, Riazantseva NV, Chasovskikh NIu, Starikova EG, Akad Med Nauk. 2009;(4):3-7. Russian.
35. Nakshatri H, Bhat-Nakshatri P, Currie RA. Subunit association and DNA binding activity of the heterodimeric transcription factor NF-Y is regulated by cellular redox. J Biol Chem. 1996;271:28784-28803.
36. Wartenberg M, Fischer K, Hescheler J, Sauer H. Redox regulation of P-glycoprotein-mediated multidrug resistance in multicellular prostate tumor spheroids. *Int J Cancer*. 2000;85:267-274.

37. Wartenberg M, Ling FC, Schallenberg M, Bäumer AT, Petrat K, Hescheler J, Sauer H. Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species. *J Biol Chem*. 2001;276:17420-17428.

38. Uchiumi T, Kohno K, Tanimura H, Matsuo K, Sato S, Uchida Y, Kuwano M. Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. *Cell Growth Differ*. 1993;4:147-157.

39. Miyazaki M, Kohno K, Uchiumi T, Tanimura H, Matsuo K, Nasu M, Kuwano M. Activation of human multidrug resistance-1 gene promoter in response to heat shock stress. *Biochem Biophys Res Commun*. 1996;51:1427-1436.

40. Hirsch-Ernst KI, Ziemann C, Foth H, Kozian D, Schmitz-Salue C, Kahl GF. Induction of mdr1b mRNA and P-glycoprotein expression by tumor necrosis factor alpha in primary rat hepatocyte cultures. *J Cell Physiol*. 1998;176:506-515.

41. Fardel O, Lecureur V, Corlu A, Guillouzo A. P-glycoprotein induction in rat liver epithelial cells in response to acute 3-methylcholanthrene treatment. *Biochem Pharmacol*. 1996;51:1427-1436.

42. Tainton KM, Smyth MJ, Jackson JT, Tanner JE, Cerruti L, Jane SM, Darcy PK, Johnstone RW. Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. *Cell Death Differ*. 2004;11:1028-1037.

43. Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. *Blood*. 1999;93:1075-1085.

44. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. *EMBO J*. 1991;10:2247-2258.

45. Moloney JN, Cotter TG. ROS signalling in the biology of cancer. *Semin Cell Dev Biol*. 2018;80:50-64.

46. Burdon RH, Gill V, Alliagana D. Hydrogen peroxide in relation to proliferation and apoptosis in BHK-21 hamster fibroblasts. *Free Radic Res*. 1996;24:81-93.

47. Kang CD, Ahn BK, Jeong CS, Kim KW, Lee HJ, Yoo SD, Chung BS, Kim SH. Downregulation of c-jun/SAPK activity is associated with the cross-resistance to P-glycoprotein-related drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein. *Exp Cell Res*. 2000;256:300-307.

48. Osborn MT, Chambers TC. Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. *J Biol Chem*. 1996;271:30950-30955.

49. Barancik M, Bohacová V, Kvackajová J, Hudecová S, Krizanová O, Breier A. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. *Eur J Pharm Sci*. 2001;14:29-36.

50. Ding S, Chamberlain M, McLaren A, Goh L, Duncan I, Wolf CR. Cross-talk between signalling pathways and the multidrug resistant protein MDR-1. *Br J Cancer*. 2001;85:1175-1184.

51. Abrams SL, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Baecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. *Biochim Biophys Acta*. 2007;1773:1263-1284.

52. Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Baecke J, Stivala F, Dania M, Nicoletti F, Libra M, Martelli AM, McCubrey JA. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. *Cell Cycle*. 2010;9:1781-1791.

53. Hollmann CA, Owens T, Nalbantoglu J, Hudson TJ, Sladek R. Constitutive activation of extracellular signal-regulated kinase predisposes diffuse large B-cell lymphoma cell lines to CD40-mediated cell death. *Cancer Res*. 2006;66:3550-3557.

54. Kulich SM, Chu CT. Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson’s disease. *J Neurochem*. 2001;77:1058-1066.

55. Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. *J Biol Chem*. 2000;275:39435-39443.

56. Joneson T, White MA, Wigler MH, Bar-Sagi D. Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS. *Science*. 1996;271:810-812.